Microsoft’s Xbox to Cut 3200 Jobs, Divest Studios in Overhaul

6 Jul 2026 · 25 min · 16 chapters

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

The Bloomberg Intelligence Podcast episode covers multiple business stories. Main tech segment: Microsoft’s Xbox plans to cut about 3,200 jobs (~20% of staff) over the next year and divest studios as part of a broader Microsoft headcount reduction (~6,400). Guest Brody Ford (Bloomberg technology reporter) says Xbox’s operating margins are 3–10x lower than comparable businesses, so Microsoft is reorienting toward a more profitable platform while selling content-making studios. Key drivers include AI-driven capex/data-center spending and a component/memory crunch that squeezes console margins; Microsoft’s Activision acquisition ($69B) hasn’t delivered expected margins. Examples: memory chip price spikes; AI-created competition for eyeballs. Other segments: SK Hynix’s ~$28B ADR IPO in the U.S. (Bailey Lipschultz, equities reporter) and Novartis buying Myrrix Bio up to $1.5B for tumor-targeted cancer drug delivery (Sam Fazelli, pharma analyst).

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Chapters

Tap a time to open that second in VO

Exploring AI Integration in Business

0:00 to 1:00

Learn how AI is transforming workforce operations at IBM.

“So there's a lot of noise about AI, but time's too tight for more promises.”

Microsoft's Xbox Job Cuts and Strategy

2:18 to 4:36

Discussion on Xbox's job cuts and Microsoft's strategic shifts.

“Brody Ford, Bloomberg technology reporter, joins us here.”

Financial Implications of Xbox Changes

4:36 to 7:00

Insights into the financial performance and future risks of Xbox.

“I think a lot of people forget about the Activision acquisition a couple of years ago.”

Upcoming Earnings and Market Reactions

7:00 to 7:56

Anticipation around Microsoft's upcoming earnings report.

“choppiness over the market of recent years.”

Upcoming Earnings and Market Reactions

7:57 to 8:48

Anticipation around Microsoft's upcoming earnings report.

“Support for the show comes from public.com.”

SK Hynix IPO and Market Impact

9:26 to 14:00

Analysis of SK Hynix's upcoming IPO and its implications.

“Start your day with Bloomberg Daybreak, the podcast with a global view on the stories that matter.”

Investors' Insights on SK Hynix IPO

14:00 to 15:53

Discussion about the SK Hynix IPO and investor sentiment.

“We do know a few investors that we spoke to for our story that went out Sunday morning.”

Investors' Insights on SK Hynix IPO

15:57 to 16:44

Discussion about the SK Hynix IPO and investor sentiment.

“If you're actively involved in your portfolio, you probably catch yourself repeating the same actions.”

Companies to Watch: Part 1

18:08 to 19:59

Discussion on 10 companies to watch in Q3, focusing on Microsoft.

“You're listening to the Bloomberg Intelligence Podcast.”

Companies to Watch: Barbie and Mattel

20:00 to 21:19

Analysis of Mattel's performance in light of Barbie's sales trends.

“biggest, LLM cloud platforms that are being used.”
Show all 16 chapters

Energy Security in Europe: SolarEdge

21:20 to 22:41

Exploration of SolarEdge's opportunities amid energy challenges in Europe.

“I liked, you know, the face-off against tech and screens and all that, but I digress.”

Hong Kong Land and Market Recovery

22:42 to 23:58

Discussion of Hong Kong's market recovery and real estate outlook.

“But the European opportunity is what's driving revenue surprise.”

Novartis Acquires Myrix Bio

24:19 to 28:00

Analysis of Novartis's acquisition of Myrix Bio and its implications.

“Just describe what you want to do in plain English.”

The Novartis Acquisition: Insights and Implications

28:00 to 29:46

Explore the implications of Novartis's significant acquisition and the factors that influenced its large upfront payment.

“So nothing seemed to have come out of that.”

Market Position and Drug Pipeline Analysis

29:46 to 31:04

Discussion on Novartis's stock performance and the potential longevity of its key drug, Cosentix.

“And here, I think they're going into this.”

Strength in the Pharmaceutical Sector

31:04 to 33:07

Examine the financial strength of major pharmaceutical companies and their capacity for mergers and acquisitions.

“You mentioned the Lilly deals, and we know that Lilly is operating from a position of strength, being able to go out and build up its pipeline in a way that perhaps other drug makers aren't able to.”
Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00So there's a lot of noise about AI, but time's too tight for more promises. So let's talk about results. At IBM, we work with our employees to integrate technology right into the systems they need. Now, a global workforce of 300 ,000 can use AI to fill their HR questions, resolving 94 % of common questions. Not noise. Proof of how we can help companies get smarter by putting AI where it actually pays off, deep in the work that moves the business. Let's create smarter business. IBM. When you're running a business, the best days are the ones where priorities stay on track. For midsize and large companies, risk can affect multiple parts of the organization at once, from property and liability to cyber and regulatory challenges.

0:43At that level, managing risk becomes an ongoing discipline. At the Hartford, the focus is on helping businesses manage risk before it turns into something more disruptive. And when losses do happen, that work is paired with insurance coverage shaped by years of underwriting, risk engineering, and claims experience. Learn more at thehartford.com slash risk mitigation. Policies provided by Hartford Fire Insurance Company and its property and casualty affiliates, Hartford, Connecticut.

1:10Scarlet Fu:When you own your own business, you own every decision. Now own the card that rewards you for it. Chase Sapphire Reserve for Business is a pay-in-full card that elevates your travel experience and offers premium benefits that will take your business to the next level. Sapphire Reserve for Business offers 8x points on all purchases through Chase Travel, 3x points on social media and search engine advertising, airport lounge access, and more. Chase Sapphire Reserve for Business. It's the card that gives back all you put in. Learn more at chase.com forward slash reserve business. Chase for Business.

1:44Scarlet Fu:Make more of what's yours. Accounts subject to credit approval. Restrictions and limitations apply. Cards are issued by JPMorgan Chase Bank N.A., member FDIC. Bloomberg Audio Studios. Podcasts. Radio. News. You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10 a.m. Eastern on Apple CarPlay and Android Auto with the Bloomberg Business App. Listen on demand wherever you get your podcasts or watch us live on YouTube. Pieces of news coming across the tape here this morning on the tech side is Microsoft's Xbox unit plans to cut 3 ,200 jobs and divest studios in another overhaul here.

2:29Brody Ford, Bloomberg technology reporter, joins us here. Brody, what's going on at Microsoft here today? Pretty much across the industry of technology, you see companies trying to rethink where they're spending money. A lot of this is fueled because they're spending so much on AI and building out data centers and infrastructures that they're taking a closer look across all divisions. So today, Xbox is the one that we see really kind of getting that hammer. They laid out a plan to cut about 20 % of staff over the next year. And broader at Microsoft, it's a plan to cut about 6 ,400 people. again, just kind of trimming both an Xbox and sales, trying to reorient for what they say will help them grow in this next era.

3:17Scarlet Fu:Brody, what is the rationale for Microsoft keeping Xbox? The CEO of the Xbox division wrote in a note to staff this morning, and this is based on your reporting, that Xbox is operating at margins three to 10 times lower than comparable businesses. I mean, financially, it's not keeping up. So why does Microsoft want to keep it? It's a good question. Microsoft really has traditionally struggled with consumer businesses. You know, every time they've kind of tried to spin up, say, like a smartphone or things of this nature over history, it hasn't always gone super well. Xbox, they've been traditionally committed to because it was this unique blend of hardware and software, and they found a niche in it.

3:57And, yeah, today is them trying to reorient that business into something that they can keep and grow for the long term. So you see them spinning off a lot of studios, talking about how owning content makers maybe isn't a business they want to be in. But owning the platform is something they're still interested in doing. How much is Xbox? Do we know of their total revenue? Like, how material is it for the financials of this company? It's a decent chunk of revenue, right? I mean, the issue is the profit. A lot of people buy video games. A lot of people buy consoles. But, you know, Microsoft has really struggled to make it super profitable.

4:37I think a lot of people forget about the Activision acquisition a couple of years ago. I mean, I think I was like$69 billion. It was one of the biggest tech acquisitions of all time. And yet a couple of years later, we find that the margins haven't kept up. The growth isn't quite what they hoped it would be. Of course, we have the component crunch, right? A lot of things like chips and memory have increased in price, which kind of accelerate all of these issues. So it is a material business for Microsoft. It's something they're ready to throw away, but it's something that they feel they need to really kind of take a closer look at.

5:12Scarlet Fu:I know you don't cover Sony per se, but how do Xbox's fortunes compare with, say, the Sony PlayStation? A lot of console makers are struggling right now because of that memory crunch, because AI has essentially messed with the supply chains for a lot of different components that go into computers and infrastructures. And so if you're a console maker that's already running at pretty slim margins, then all of a sudden your memory chips double in price. That's going to make everything tough. and more broadly content makers are needing to compete against you know a wider variety of content that's able to be created with ai i mean as it relates to triple a games they're not you know being created with ai but there's just so many more places for eyeballs to be focused on these days that if you're selling content it's a more competitive market microsoft stocks down 20 year to date it's it's rare that you see that kind of performance out of microsoft or What's the feeling within the offices that they're Redmond, Washington?

6:15I mean, do they talk about their stock? Do they ignore their stock? How do they kind of just talk about it, think about it? When you ask an executive, they say, oh, I don't care about the stock price. I focus on executing. You ask an employee and they say, what the heck is going on with our stock price? And that's consistent across all companies. The big thing for Microsoft, and you can see other hyperscales, you can see with Oracle very well, is that on one hand, Wall Street is worried about all this spending. Is it going to pay off all the data centers? And on the other end, there are traditional software businesses that have really created the cash cow that is Microsoft.

6:54Does that last in the age of AI? So they kind of have these two concurrent fears, which are leading to, yeah, some weakness for a stock that has been just a pretty consistent, safe harbor and so much choppiness over the market of recent years.

7:07Scarlet Fu:Brody, I know you cover Microsoft, that company is going to be reporting its quarterly results at the end of this month. Will this Xbox closure, do you think, result in some surprising financials on earnings day? What I would expect to hear them talk about is ongoing focus on margins, which, you know, is corporate speak for we're planning to fire 20 percent of people at Xbox. You know, I think we'll hear them talk about how, look, we're spending a ton of money on our data centers on our chips, our CapEx is in the past hundreds of billions of dollars a year. But we're doing what we can to trim costs everywhere.

7:45And we're going to make sure that we're really getting an ROI out of every dollar. I think that will be the high level message. And if you poke underneath it, you see phenomenon like the cost cuts today.

7:55Scarlet Fu:Stay with us. More from Bloomberg Intelligence coming up after this. Support for the show comes from public.com. If you're actively involved in your portfolio, you probably catch yourself repeating the same actions. Buying the dip, manually sweeping idle cash, putting on a hedge. On public, you can now create AI agents that handle all these tasks on your behalf. Just describe what you want to do in plain English. Like, if the VIX hits 25, buy a put option on the S &P 500. Or, if my cash balance goes above$20 ,000, move the excess into my direct index. You approve the workflow and your agent handles the rest.

8:33Monitoring the market, watching for your conditions, and executing your strategies exactly as defined. An investing platform driven by your intent, not just your clicks. You can also get full read and write access to your account via the public API. Go to public.com slash market and fund your account in five minutes or less. That's public.com slash market. Paid for by public investing. Brokerage services by Open to the Public Investing, Inc., member FINRA, and SIPC. Advisory services by Public Advisors, LLC, SEC Registered Advisor. Complete disclosures available at public.com slash disclosures.

9:10If your best finance people are doing expense reports, chasing receipts, or spending time on month-end close, it's time to get Brex AF, a Gentic finance that eliminates that work before it starts. Learn more at brex.com slash AF.

9:25Scarlet Fu:Get the news you need in just 15 minutes. Start your day with Bloomberg Daybreak, the podcast with a global view on the stories that matter. I'm Nathan Hager. And I'm Karen Moscow. Join us each morning for curated stories on current events, politics, business and foreign relations. Plus one conversation on the day's biggest developments, all in just 15 minutes. Subscribe to Bloomberg Daybreak for a precise, thoughtful take on the stories that matter. Listen to Bloomberg Daybreak each morning on Apple, Spotify or anywhere you listen.

10:11Believe it or not, kind of flying under the radar screen here. We're kind of getting a quasi IPO coming soon. SK Hynix, the Korean company, they make all the memory chip stocks up like a gajillion percent. they're going to list 17.79 million shares ADRs in the U.S. And I think that's, if my math is correct, that's like a$28 billion offering. I mean, we're kind of getting numb to these huge numbers with Goldman. I mean, Google doing their secondary earlier this year and all the big IPOs we've seen with SpaceX. But let's put it in context here. We can do that with Bailey Lipschultz, senior equities reporter for Bloomberg News.

10:46Bailey, talk to us about what SK Hynix is doing here. Yeah. So this is a company, to your point, nominally at 28 billion would be the third largest IPO ever on any exchange. So behind SpaceX, behind Saudi Aramco, which is pretty mind boggling to be completely honest. The thing to keep in mind is so this is an ADR, ADR IPO. So basically they're selling shares for the first time here in the U.S. They will maintain a home listing on the other side of the world in South Korea. Each ADR represents one tenth of one common share. Why does that all matter? a as you mentioned a 28 billion dollar offering is very large b this is a company worth more than a trillion dollars and c this opens up everyone on wall street everyone in the u.s to now actually trade sk hynix on new york hours on u.s hours and be able to cater to not only retail investors but institutional investors we already saw bailey gifford co2 and situational awareness partners indicating they want to buy as much as$7 billion of this deal.

11:46So big numbers, but it's also a right time for the company. Timing. I've heard people talk about maybe this feels a little top of the market kind of thing. Are you hearing that out in the marketplace? Yeah. When we talk to people, the main question is, can we structurally say this time is different? And why does that matter for semiconductors? Semiconductors are the most cyclical business on Wall Street. So this is an industry that booms and busts as kind of the PC and smartphone eras evolve and as sales kind of mature from there. The big question is, will we continue to see demand for building out data centers?

12:23Will we continue to see that here on Earth and potentially as SpaceX wants to do in space? And the big question from there goes, these are companies that want to spend hundreds of billion dollars to build out manufacturing capacity. Right now, there's a bottleneck to get compute and get access to these chips. Well, what happens if it's not that easy? And that's the big risk. So just from a U.S. listing perspective, is this going to go in various indices? Is SK Hynix in the various indexes around the world? It's in some. When you just kind of look using the WGT function, which will pull up which indexes the company is in.

13:03Obviously, again, it's one of the bigger companies in the world. So it's obviously a big driver behind the KOSPI, the Korean exchange. It's also in a number of those emerging market ETF, emerging market indexes. The big thing to keep an eye on and the big thing that does matter is it's not eligible for fast track NASDAQ 100 inclusion. But in the long run, it will likely be included in the NASDAQ 100 and everything that that brings. Obviously, we talked about that with SpaceX. That is a fundamental shift for a company, again, that has been very difficult to trade for U.S. investors. And then the question from there goes, OK, do we get to see double and triple or triple levered ETFs and kind of what happens with that entire explosion from there?

13:44So will this open up new buyers, I guess, potential new owners for this stock? Yeah, when we've spoke with a number of institutional investors, whether they couldn't trade companies that are listed in an emerging market, whether they just don't want the headache of worrying about foreign exchange and hedging some of those risks, those have been top of mind. We do know a few investors that we spoke to for our story that went out Sunday morning. There also are investors who just aren't comfortable with an ADR. They want to own companies that are domiciled here. They want to own companies that their primary listing is in the U.S.

14:18as opposed to this. It'll be interesting to see what kind of premium it trades at. This is kind of ripping off the playbook that we saw with Taiwan Semi. But again, that was a company that raised a few hundred million, not closer to 30 billion. What's the timing of this deal? It'll price and it'll trade on Friday. We expect pricing to happen sometime Thursday morning here so that it would open up, kind of making sure that people are able to trade accordingly in South Korea there Friday morning. It's a truncated process. It's a quicker process. But even talking to the bankers on the deal, if you want to invest in SK Hynix, you probably know who the company is and you're not selling a new entire pitch.

14:54The one thing that we've been pointing out is their main roadshow at 1.30 p.m. New York time will be the only real interaction with management on a webcast for potential it's two. So they're just on a webcast. Kind of a webcast. Very quick process. Again, it's tied to it. Yeah. I'm overcomplicated. Just another great day to be an IPO banker, right? Yeah, they're making, I think it was 50 biffs on this deal. So we had a few bankers who said, you know, this isn't easy. But when you compare to being at the beck and call of Elon Musk, night and day between the SpaceX IPO. Exactly. And how about Anthropics?

15:30That's still thinking maybe fall, late fall, something like that? We've heard nothing to change expectations around that September, October timeframe. obviously, potential delay of open AI into next year becomes a question of if you're anthropic, do you need to race and get out in September? Or do you want to have a better kind of visibility into your business maybe in that October, November timeframe?

15:52Scarlet Fu:Stay with us. More from Bloomberg Intelligence coming up after this. Support for the show comes from public.com. If you're actively involved in your portfolio, you probably catch yourself repeating the same actions. Buying the dip, manually sweeping idle cash, putting on a hedge. On public, you can now create AI agents that handle all these tasks on your behalf. Just describe what you want to do in plain English. Like, if the VIX hits 25, buy a put option on the S &P 500. Or, if my cash balance goes above$20 ,000, move the excess into my direct index. You approve of the workflow and your agent handles the rest.

16:29Monitoring the market, watching for your conditions, and executing your strategy Exactly as defined. An investing platform driven by your intent, not just your clicks. You can also get full read and write access to your account via the public API. Go to public.com slash market and fund your account in five minutes or less. That's public.com slash market.

17:03Disclosures available at public.com slash disclosures. Ask yourself, what are your best people spending their time on right now? Expense reports, receipt chasing, month-end close that takes weeks. You become what you spend on, and that's not what you're building toward. Brex is the intelligent finance platform that eliminates that work before it starts. AI agents that handle the manual stuff automatically, so your team can spend their time on what actually compounds. It's time to get Brex AF. Learn more at brex.com slash AF.

17:36Scarlet Fu:The Bloomberg Sustainable Business Summit returns to Singapore on July 22nd. Our fifth annual Asia-Pacific Summit will explore how business and finance leaders are shaping the next phase of globalization by strengthening resilience and driving a multi-speed energy transition across Asia's diverse markets. Join us for solutions-driven discussions and networking opportunities. Thank you to our summit advisor, Bangkok Bank. Learn more at bloomberglive.com slash SBS-Singapore. You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10 a.m. Eastern on Apple CarPlay and Android Auto with the Bloomberg Business App.

18:17Scarlet Fu:Listen on demand wherever you get your podcasts or watch us live on YouTube. We want to go now to our colleague in London who, along with his colleagues, have put together a list of 10 companies to watch for in the third quarter of 2026. There are companies that dabble in chips, chocolate and Barbie. So let's check in with Tim Craighead. He is our global chief content officer on the 10 companies that you want to watch for right now. Good morning, Tim. What's the first one you would want to highlight? Well, if you don't mind, I'll give you just a little bit of context on this. just to put it into some perspective.

18:53I think you've set it up quite well, but I would just simply add that these 10 are part of a broader group of what we call focus ideas, which are high conviction, fundamental views that our analysts have across sectors across the globe. There's about 160 of them. And the reason why we got to these 10 is that they all have timely catalysts coming up in the third quarter that we think can change the market perception, company by company. And look, the biggest one, it's in AI, it's very much, it seems like, out of favor is Microsoft. This is a stock that has been under pressure since last autumn, even while other hyperscalers like Amazon and Google have been trading better in the semiconductor companies, clearly, that are all AI-driven, have been on fire.

19:51And, you know, bottom line, it seems like the perception is that Microsoft is going to be disrupted, you know, to use the buzzword. But in our perspective, you know, they've got one of the biggest, if not the biggest, LLM cloud platforms that are being used. And they've got a new Microsoft 365 suite that comes out in the second half, we think both of those can continue to drive revenue that's going to positively surprise. Barbie, Mattel, what's the story there, Tim? Yeah, well, the interesting thing with this is not all of these focus ideas, not all of these 10 companies are constructive, positive calls.

20:36There's also ones where we're cautious or concerned. And that's the case with Mattel. there was a nice big surge in doll demand, Barbie demand in and around the Barbie movie a couple of years ago going back to your stomping around, Paul, in media and what we've seen since then is a progressive shift more towards building sets and trading cards in terms of what's cool in the world of toys, dolls or not And we think that there's continued disappointment from the standpoint of doll sales, specifically Barbie, as we look through the second half of the year.

21:19Scarlet Fu:I did see Toy Story, and I feel like, you know, maybe that gives a little bit of a jumpstart to some toys. You saw Toy Story 5? Toy Story 5. And what did you think? I liked it. Oh, good. Yeah, it was good. I liked, you know, the face-off against tech and screens and all that, but I digress. Tim, I wanted to get in. We will hear. Yeah, we will hear more about that in their earnings release. OK, so that is something we can update as we get closer to that. I want to get to a European company as well, because you have SolarEdge as a company to watch for in Europe. And I think about what's going on with the heat wave there and how energy security continues to be an issue for the continent.

21:58Yeah, it is all about energy security. and it's been lit up obviously yet again in the wake of the crisis or the conflict in the Middle East. It started to begin with Russia, Ukraine and Europe is in the hot seat, no pun intended. And the ramp up that we're seeing in terms of solar equipment related orders, we think will continue to surprise. It's been recovering for a couple of quarters, and we think that there is more to come and not fully yet appreciated. But it is all about its European business, even though I think it's actually based in Illinois. But the European opportunity is what's driving revenue surprise.

22:52Hong Kong Land. What is this company and why should we be paying attention? Yeah, so if either of you or any of the listeners have been to Hong Kong, one of the iconic buildings right on the central Hong Kong business district waterfront has these famous circular windows. That's these guys building along with many others. And the whole thing that's going on with Hong Kong in terms of office is it's coming back to life. You know, it was under a significant amount of pressure post-pandemic and the national security law being implemented. People were leaving. Businesses were leaving. But they are now coming back.

23:40There's a surge in the Hong Kong stock exchange. IPOs are alive. The financial markets are alive. Professionals are coming back. And rents are rising, and that asks out value for Hong Kong land specifically, we think is on the upswing.

23:57Scarlet Fu:Stay with us. More from Bloomberg Intelligence coming up after this.

24:18on your behalf. Just describe what you want to do in plain English. Like, if the VIX hits 25, buy a put option on the S &P 500. Or, if my cash balance goes above$20 ,000, move the excess into my direct index. You approve the workflow and your agent handles the rest. Monitoring the market, watching for your conditions, and executing your strategies exactly as defined. An investing platform driven by your intent, not just your clicks. You can also get full read and write access to your account via the public API. Go to public.com slash market and fund your account in five minutes or less. That's public.com slash market.

Read the full transcript

24:58Paid for by Public Investing. Brokered services by Open to the Public Investing, Inc., Member FINRA, and SIPC. Advisory services by Public Advisors, LLC, SEC Registered Advisor. Complete disclosures available at public.com slash disclosures. If your best finance people are doing expense reports, chasing receipts, or spending time on month-end clothes, it's time to get Brex AF, a gentic finance that eliminates that work before it starts. Learn more at brex.com slash AF.

25:28Scarlet Fu:This week on Leaders with me, Francine Lacqua. I speak to tennis legend Rafa Nadal about how he stayed competitive despite injury. I was able to enjoy the victories probably more than if I will not have this issue. One iconic match. In my mind was, I am almost dead. And whether he misses playing. I don't miss tennis because there was nothing else to offer. Listen and watch Leaders with me, Francine Lacqua, on Bloomberg Television or wherever you get your podcasts.

26:01Scarlet Fu:You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10 a.m. Eastern on Apple CarPlay and Android Auto with the Bloomberg Business App. Listen on demand wherever you get your podcasts. or watch us live on YouTube. Novartis agreed to buy British biotech Myrix Bio for as much as$1.5 billion, adding an experimental cancer drug designed to deliver more potent treatments directly to tumors while limiting damage to healthy cells. Let's break it down. Plus, all the healthcare news. We can do that with Sam Fazelli. He's the director of research, and he's a pharmaceutical analyst for Bloomberg Intelligence.

26:38He's based in London. Sam, talk to us about Novartis. kind of what are their strengths where do they need to get better and what are they doing with this particular deal so paul first happy post fourth of july to you guys all uh for your independence from the british um all those years 250 years ago and and to the audience obviously so here here we have novartis buying a a cancer drug company novartis is already quite active in cancer. In fact, one of the areas that they are quite active in is getting radioactive material to your tumor rather than you going to get radiation from an external beam or a machine.

27:24This is things that are kind of trying to target the tumor, particularly prostate cancer in this case, that they've got a marker on prostate cancer cells, get radioactivity in there. But one of the other things that has been evolving very rapidly recently is getting chemotherapy directly to the tumor rather than injecting it all over the body. The hope being that you can reduce the side effect profile and increase the efficacy. That's what this new deal is. And this is something relatively new for them. They had deals like this before. When you look back at 2013 and 2016, they had done some of these antibody drug conjugate type deals.

27:58But obviously, that's over 10 years ago for the later deal. So nothing seemed to have come out of that. So this is their back into that space. And I think it's quite an interesting, clever deal. Big upfront number, though. That's quite interesting. One point one billion dollars cash upfront.

28:14Scarlet Fu:So I'm glad you bring up that point, that idea of big upfront payments. Is that the new norm now in these kinds of deals? So I I don't know how competitive this deal was. I'm hoping to talk to some of the founders who I know because they're in our backyard. to try and understand what was it that attracted Novartis so strongly to this. This is a British biotech company, so that means automatically that they're not necessarily able to go and raise hundreds of millions from the local market. They are in preclinical stage or very close to at least what publicly available information we have is preclinical.

28:56and so this is a rich number for such an early company and there's very little chance that they would have been able to go public so why novart is paid so much up front rather than do what usually happens i.e pay a smaller amount and leave the rest of it for a milestone in in a year two three years time it's going to be interesting to find out they do have some very clever chemistry in here and this is not just an ordinary for want of a better phrase not that any of these drugs are ordinary antibody drug conjugate. They have new drugs that they're trying to get into the tumors. So that's interesting.

29:34What's the call out there on Novartis stock these days, Sam? What do people have to kind of believe here to jump on this one? Yeah, so the shares have been doing reasonably well. The company's got a decent pipeline. One of their big drugs is Cosentix, which is not for oncology it's for psoriasis and and that type of disease arthritis type diseases or autoimmune diseases let's call it that way and that's a big drug and some people are worried about it going off patent like every pharma company that's the rule of the game with them we think in our group that Cosentix has got a longer life than people think and so you know they have an active oncology business where there's some, again, same sort of story, but with those radio chemicals, if you remember, I'll just highlight it, and a whole bunch of other drugs that are coming on.

30:27And here, I think they're going into this. This is going to be a long way off in terms of paying back because it's pretty clinical early phase, right? So it's going to be five, 10 years, eight years. So it's not aimed at today's problems. It's a bit like the type of lily deals we were talking about last week, which are some early deals that are being designed to make sure the company has got assets to keep thriving going forward. And this can pay off in many different ways. Remember, these chemicals can be attached to any antibody to attack different types of tumors. So it's a platform.

30:59Scarlet Fu:It's a platform and everyone's trying to build one. Let me get your thoughts, Sam, overall on M &A in the space. You mentioned the Lilly deals, and we know that Lilly is operating from a position of strength, being able to go out and build up its pipeline in a way that perhaps other drug makers aren't able to. Who else is operating from that kind of position of strength in addition to Eli Lilly? Yeah, so Merck has got a pretty good cash flow position. AstraZeneca has got strong cash flow. GSK did a deal, one of the deals we spoke about recently. So most of the pharma companies are in a pretty decent shape.

31:33AbbVie, you know, they've got great, great growth and you can see analysts are upgrading their stock on almost a daily basis. So most companies do, Pfizer is the one that has done its M &A to a degree. And now we're waiting for that to bear fruit. The latest one, they have done other deals. They have been doing licensing and partnership deals. So most pharma companies are in a position of strength from a cash flow perspective to be able to do these types of deals. And their balance sheets are relatively light across the sector as a whole. And so there's access to credit there too if they wanted to.

32:09Scarlet Fu:This is the Bloomberg Intelligence Podcast, available on Apple, Spotify, and anywhere else you get your podcasts. Listen live each weekday, 10 a.m. to noon Eastern on Bloomberg.com, the iHeartRadio app, TuneIn, and the Bloomberg Business app. You can also watch us live every weekday on YouTube and always on the Bloomberg Terminal.

32:36When you're running a business, the best days are the ones where priorities stay on track. For midsize and large companies, risk can affect multiple parts of the organization at once, from property and liability to cyber and regulatory challenges. At that level, managing risk becomes an ongoing discipline. At the Hartford, the focus is on helping businesses manage risk before it turns into something more disruptive. And when losses do happen, that work is paired with insurance coverage shaped by years of underwriting, risk engineering, and claims experience. Learn more at thehartford.com slash risk mitigation.

33:11Policies provided by Hartford Fire Insurance Company and its property and casualty affiliates, Hartford, Connecticut. If your best finance people are doing expense reports, chasing receipts, or spending time on month-end close, it's time to get Brex AF, a Gentic finance that eliminates that work before it starts. Learn more at brecks.com slash AF. Hi, I'm Barry Ritholtz, inviting you to join me for the Masters in Business podcast. Every week, we bring you conversations with the people who shape markets, investing, and business. I speak with CEOs, Nobel laureates, market innovators, and legendary investors.

33:49Whether you own stocks, bonds, real estate, commodities, even crypto, these are discussions you absolutely need to hear. Subscribe to the Masters in Business podcast on Apple, Spotify, or anywhere you listen.

From the publisher

Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF. 

Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu 

- Brody Ford, Bloomberg Technology Reporter, discusses Microsoft Corp.'s Xbox plans to eliminate 3,200 jobs, or around 20% of its staff over the next year, as part of a massive reorganization to spur growth in the struggling gaming division. Xbox will divest four of its video-game development studios and is beginning the process to part ways with a fifth, with the goal of streamlining the business and reinvesting in bigger projects.

- Bailey Lipschultz, Bloomberg News Senior Equities Reporter, discusses SK Hynix kicking off the formal marketing process for its US listing, seeking to sell American depositary receipts representing about 17.79 million common shares. The company is looking to capitalize on surging investor demand for the high-flying memory-chip sector, with the offering of ADRs coming after the firm’s Seoul-traded stock rallied about 260% this year.

- Tim Craighead, Bloomberg Intelligence Global Chief Content Officer, discusses 10 companies to watch in Q3. Bloomberg Intelligence analysts have identified interesting companies from their roster of high-confidence Focus Ideas. Spanning sectors and regions, each scenario outlines a catalyst in the next few months that supports our case.

- Sam Fazeli, Bloomberg Intelligence Director of Research: Healthcare, Defence, Industrials & Autos, discusses Novartis AG agreeing to buy Myricx Bio for as much as $1.5 billion, adding an experimental cancer drug designed to deliver more potent treatments directly to tumors while limiting damage to healthy cells.

 

See omnystudio.com/listener for privacy information.

More from Bloomberg Intelligence

All 414 episodes
Microsoft’s Xbox to Cut 3200 Jobs, Divest Studios in OverhaulBloomberg Intelligence · 25 min
Listen in VO